** Shares in Gubra GUBRA.CO surge 29% at market open after the Danish biotech company signed a licensing deal with AbbVie ABBV.N to develop an amylin analog for obesity treatment
** The partnership marks AbbVie's entrance into the obesity field, the companies say in a press release
** Terms of the deal include $305 million as an upfront payment to Gubra and $1.875 billion in potential milestones, they add
** Analysts at Van Lanschot Kempen view the terms as "attractive", saying they appear to be higher than the broker's valuation
** Kempen adds AbbVie is a good partner for Gubra, as it can accelerate mid- and late-stage development of the GUBamy amylin analog programme, while offering infrastructure for a commercial launch
** Gubra's shares were up 19% by 0824 GMT, on track for their best day ever
(Reporting by Vera Dvorakova)
((vera.dvorakova@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。